Reaction
B-Cell Lymphoma Refractory reporting signals
As of the last recalculation, B-Cell Lymphoma Refractory appears in 89 FAERS reports alongside 6 co-occurring drug terms. The strongest observed disproportionality signal is DOXORUBICIN (PRR 227.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Doxorubicin | 44 | 227.4 | 227.5 |
| Doxorubicin Hydrochloride | 23 | 221.8 | 221.9 |
| Ifosfamide | 14 | 180.6 | 180.8 |
| Bendamustine Hcl | 10 | 169.8 | 169.9 |
| Thiotepa | 4 | 102.5 | 102.6 |
| Polatuzumab Vedotin | 3 | 74.4 | 74.4 |